Return to ads
All categories


Posted by
Posting ads for 49 years
NEW YORK, May 4 (Reuters) - InterMune Inc (ITMN.O) said U.S.

health regulators refused to approve its drug to treat lung scarring and asked for a new clinical trial to prove it works, sending its shares down 80 percent

Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff